Advanced Biologics' OsteoAMP&#0174 Provides Additional Evidence of Superiority Over rhBMP-2

Published: Oct 23, 2012

LADERA RANCH, Calif., Oct. 22, 2012 /PRNewswire/ -- Advanced Biologics announced today that they will be releasing data at the North American Spine Society (NASS) annual meeting this week in Dallas, TX showcasing a clinical study demonstrating superior lumbar fusion rates for OsteoAMP® when compared to rhBMP-2 (Infuse®, Medtronic). In a blinded, multi-center clinical and radiological study, fusion analysis of 221 patients showed superiority for OsteoAMP® in producing fusions when compared to rhBMP-2. Fusions (TLIF/LLIF) were assessed by a blinded independent radiologist at various time points (3months, 6months, 12months and 18months) for both OsteoAMP and rhBMP-2. Analysis showed superiority for OsteoAMP at all time points (p<0.03). In addition, the study revealed that patients in the rhBMP-2 arm had 5 times greater the amount of radiographically assessed complications (ectopic bone formation, osteolysis) as the OsteoAMP® arm. The study has been peer reviewed and accepted for publication in The Journal of Bone & Joint Surgery (Br) next year.

"The results we are receiving with OsteoAMP® clinical studies are extremely strong," stated President, Amit Govil. "They continue to substantiate OsteoAMP as a viable option for surgeons, hospitals and patients searching for a cost-effective and safer option than rhBMP-2. We are currently enrolling patients in additional clinical trials to further validate our technology."

OsteoAMP® is an award-winning allogeneic growth factor that is a lower-cost alternative to recombinant growth factors, such as rhBMP-2 (Infuse®, Medtronic). Additionally, OsteoAMP®'s four distinctive formats (granules, compressible sponges, putty, and structural grafts) provide a distinct advantage by allowing surgeons to tailor deliver the technology according to their needs in surgery.

About Advanced Biologics

Founded in 2009, Advanced Biologics (ABC) is a privately-held company focused on developing innovative and clinically relevant biologic solutions across a wide degree of medical specialties. The OsteoAMP® family of osteoinductive/conductive products is the first line of orthobiologic offerings produced by ABC. ABC was awarded the Best New Regenerative Technology award in 2009, Best New Biomaterial Technology Award in 2010, and 2011 Best New Technology in Biomaterials and Biologics by the Orthopedics This Week Spine Technology Awards. Future development includes a shape-memory, anti-bacterial synthetic product portfolio and ventures into other fields of regenerative medicine.

SOURCE Advanced Biologics, LLC

Back to news